Jarosz Alicja, Nowak Tomasz, Szyluk Karol, Balcerzyk-Matić Anna, Iwanicki Tomasz, Iwanicka Joanna, Kalita Marcin, Gawron Katarzyna, Kania Wojciech, Niemiec Paweł
Department of Biochemistry and Medical Genetics, Faculty of Health Sciences in Katowice, Medical University of Silesia in Katowice, Medykow 18 Str., 40-752 Katowice, Poland.
District Hospital of Orthopaedics and Trauma Surgery, Bytomska 62 Str., 41-940 Piekary Slaskie, Poland.
Int J Mol Sci. 2024 Dec 7;25(23):13166. doi: 10.3390/ijms252313166.
Platelet-rich plasma (PRP) is an autologous preparation used to accelerate regeneration; however, this form of therapy is not always effective. Vascular endothelial growth factor B (), which affects vessel survival, pathological angiogenesis, and muscle development may differentiate the risk and treatment of lateral elbow tendinopathy (LET). In this study, we analyzed the influence of gene polymorphisms on the effectiveness of LET treatment with PRP. Therapeutic effectiveness was analyzed in 107 patients (132 elbows) using patient-reported outcome measures (PROMs), specifically the visual analog scale (VAS); quick version of disabilities of the arm, shoulder, and hand score (QDASH); and patient-rated tennis elbow evaluation (PRTEE), for two years (weeks 2, 4, 8, 12, 24, 52, and 104). The polymorphisms selected for the study were rs72922019, rs12366035, rs4930152, rs594942, and rs595880, being in strong linkage disequilibrium. Patients with TT (rs72922019), TT (rs12366035), AA (rs4930152), CC (rs594942), and GG (rs595880) genotypes showed better treatment effectiveness. Statistically important differences were shown for rs72922019 VAS (week 2), QDASH (weeks 0-4), and PRTEE (week 2); rs12366035 and rs4930152 VAS (week 2), QDASH (week 2), and PRTEE (weeks 2 and 4); and rs594942 and rs595880 VAS (weeks 2 and 4), QDASH (week 2), and PRTEE (weeks 2, 52, and 104). The studied polymorphisms also showed an association with blood morphological parameters, including mean platelet volume, platelet distribution width, and eosinophil levels, as well as some comorbidities (heart failure). Genotyping due to patient selection for therapy may be considered for any of the rs72922019, rs12366035, or rs4930152 polymorphisms.
富血小板血浆（PRP）是一种用于加速组织再生的自体制剂；然而，这种治疗方式并非总是有效。血管内皮生长因子B（VEGF-B）会影响血管存活、病理性血管生成和肌肉发育，它可能会区分外侧肘肌腱病（LET）的风险和治疗效果。在本研究中，我们分析了VEGF-B基因多态性对PRP治疗LET有效性的影响。我们使用患者报告结局指标（PROMs），具体为视觉模拟量表（VAS）、手臂、肩部和手部功能障碍快速评分（QDASH）以及患者自评网球肘评估（PRTEE），对107例患者（132个肘部）进行了为期两年（第2、4、8、12、24、52和104周）的治疗效果分析。本研究选择的多态性位点为rs72922019、rs12366035、rs4930152、rs594942和rs595880，它们处于强连锁不平衡状态。具有TT（rs72922019）、TT（rs12366035）、AA（rs4930152）、CC（rs594942）和GG（rs595880）基因型的患者显示出更好的治疗效果。rs72922019的VAS（第2周）、QDASH（第0 - 4周）和PRTEE（第2周）；rs12366035和rs4930152的VAS（第2周）、QDASH（第2周）和PRTEE（第2周和第4周）；以及rs594942和rs595880的VAS（第2周和第4周）、QDASH（第2周）和PRTEE（第2周、第52周和第104周）均显示出统计学上的显著差异。所研究的多态性还与血液形态学参数相关，包括平均血小板体积、血小板分布宽度和嗜酸性粒细胞水平，以及一些合并症（心力衰竭）。对于rs72922019、rs12366035或rs4930152这三种多态性中的任何一种，在治疗患者选择时可考虑进行基因分型。
